Evidence map›Paper›PMID 35491262›Full record

ArticleTrends in pharmacological sciences2022

SEAKER cells coordinate cellular immunotherapy with localized chemotherapy.

Isabel C Lane, Max Jan

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in pharmacological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Isabel C LaneMassachusetts General Hospital Center for Cancer Research, Boston, MA, USA; Massachusetts General Hospital Department of Pathology, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Max JanMassachusetts General Hospital Center for Cancer Research, Boston, MA, USA; Massachusetts General Hospital Department of Pathology, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. Electronic address: mjan@mgh.harvard.edu.

Funding

Reprogramming the chimeric antigen receptor T cell epigenome to augment anti-tumor activityK08CA255932 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAN, MAX · 2021 to 2025
$951k
NCI NIH HHS K08 CA255932
6 · The paper itself

Abstract

Tumor antigen escape and T cell dysfunction limit the effectiveness of chimeric antigen receptor (CAR) T cell therapies. To overcome these challenges, Gardner et al. engineered synthetic enzyme-armed killer (SEAKER) cells to coexpress a CAR and a prodrug-activating enzyme to orchestrate a dual immunologic and pharmacologic attack at the tumor site.

Indexed as

ImmunotherapyNeoplasmsAntigens, NeoplasmHumansImmunotherapy, AdoptiveTumor EscapeAntigens, Neoplasmcell therapysynthetic biology

Identifiers

PMID35491262
PMCPMC9883698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.